ArticleAmerican journal of ophthalmology2014
Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson Memorial Lecture.
Article in American journal of ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 75 citations in OpenAlex.
- Retinoblastoma and Its Tumor Microenvironment.Current oncology (Toronto, Ont.) · 2026Review
- Management of Retinoblastoma: A Challenge in Pediatric Ophthalmology.Life (Basel, Switzerland) · 2026Review
- High-throughput screening of drug libraries identifies a new synergistic drug combination for the treatment of retinoblastoma.PloS one · 2026Article
- HIGH-DOSE INTRAVITREAL TOPOTECAN (100 µ G/0.1 CC) AS MONOTHERAPY FOR RECURRENT/REFRACTORY INTRAOCULAR RETINOBLASTOMA IN SEVEN EYES.Retina (Philadelphia, Pa.) · 2025Article
- Tumor heterogeneity in retinoblastoma: a literature review.Cancer metastasis reviews · 2025Review
- Retinocytoma: understanding pathogenesis, diagnosis, and treatment approaches.International journal of retina and vitreous · 2025Review
- Retinoblastoma with MYCN Amplification Diagnosed from Cell-Free DNA in the Aqueous Humor.Ocular oncology and pathology · 2024Article
- Second Primary Malignant Neoplasms in Survivors of Retinoblastoma in a Single Ocular Oncology Practice.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- The Use of rAAV2-RB1-Mediated Gene Therapy in Retinoblastoma.Investigative ophthalmology & visual science · 2023Article
- Nanotechnology for Pediatric Retinoblastoma Therapy.Pharmaceuticals (Basel, Switzerland) · 2022Review
- RB1 loss triggers dependence on ESRRG in retinoblastoma.Science advances · 2022Article
- Retinoblastoma: Review and new insights.Frontiers in oncology · 2022Review
- LINC00202 promotes retinoblastoma progression by regulating cell proliferation, apoptosis, and aerobic glycolysis through miR-204-5p/HMGCR axis.Open life sciences · 2020Article
- NRAS Contributes to Retinoblastoma Progression Through SNHG16/miR-183-5p/NRAS Regulatory Network.OncoTargets and therapy · 2019Article
- Distinct Gene Expression Profiles Define Anaplastic Grade in Retinoblastoma.The American journal of pathology · 2018Article
- Improved procedural safety following protocol changes for selective ophthalmic arterial infusion of chemotherapy for treatment of ocular retinoblastoma.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2018Article
- 2-Methyl 2-butanol suppresses human retinoblastoma cells through cell cycle arrest and autophagy.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2018Article
- The value of "en toto" globe submission in the assessment of high-risk retinoblastoma cases and staging.International ophthalmology · 2018Article
- Retinal Reactive Astrocytic Tumor (Focal Nodular Gliosis): The Entity Also Known as Vasoproliferative Tumor.Ocular oncology and pathology · 2017Article
- Giant retinal tear after intra-arterial chemotherapy for advanced unilateral retinoblastoma.International journal of retina and vitreous · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purposeTo review the progress made in understanding the genetic basis, molecular pathology, and treatment of retinoblastoma since the previous Jackson lecture on the topic was published 50 years ago.
designPerspective based on personal experience and the literature.
methodsThe literature regarding retinoblastoma was reviewed since 1963. Advances in understanding the biology and treatment of retinoblastoma provided context through the author's clinical, pathologic, and research experiences.
resultsRetinoblastoma was first identified in the 1500s and defined as a unique clinicopathologic entity in 1809. Until the mid-1900s, knowledge advanced sporadically, with technological developments of ophthalmoscopy and light microscopy, and with the introduction of surgical enucleation, chemotherapy, and radiation therapy. During the last 50 years, research and treatment have progressed at an unprecedented rate owing to innovations in molecular biology and the development of targeted therapies. During this time period, the retinoblastoma gene was discovered; techniques for genetic testing for retinoblastoma were developed; and plaque brachytherapy, chemoreduction, intra-arterial chemotherapy, and intraocular injections of chemotherapeutic agents were successfully introduced.
conclusionsNearly all patients with retinoblastoma in developed countries can now be cured of their primary cancer--a remarkable achievement for a childhood cancer that once was uniformly fatal. Much of this success is owed to deciphering the role of the Rb gene, and the benefits of targeted therapies, such as chemoreduction with consolidation as well as intra-arterial and intravitreal chemotherapies. Going forward, the main challenge will be ensuring that access to care is available for all children, particularly those in developing countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.